Goldline Pharmaceutical IPO Details: Price, Dates & Financials

Goldline Pharmaceutical reports PAT margin 10.10% and EBITDA margin 20.79%.

The debt-to-equity ratio of Goldline Pharmaceutical is 1.50. A lower ratio generally means the company relies less on borrowed money.

ROE (return on equity) shows profit earned on shareholders' money, ROCE (return on capital employed) shows profit earned on all capital used in the business, and RONW (return on net worth) measures return on the company's net worth. Higher figures usually indicate more efficient use of capital.

Compare ROE, ROCE, margins and P/BV of Goldline Pharmaceutical with listed companies in the same sector, and check the peer comparison given in the offer document. Ratios are only one input — they do not predict listing gains.

We require these key ratios to evaluate the financial health, profitability, valuation, and overall performance of the Goldline Pharmaceutical IPO. They help investors understand how efficiently the company operates, how much debt it carries, and whether its shares are reasonably valued compared with its earnings and assets for that specific Goldline Pharmaceutical IPO. These ratios also help assess the Goldline Pharmaceutical IPOs ability to generate profits, manage financial obligations, and deliver sustainable growth, enabling investors to make a more informed Goldline Pharmaceutical IPO investment decision.

Investors should examine the Goldline Pharmaceutical IPO's revenue growth, profitability, debt levels, cash flow, and earnings per share (EPS). These indicators help assess the Goldline Pharmaceutical IPO's financial stability, growth potential, and investment risks before investing in the Goldline Pharmaceutical IPO.